A company that once lived off copying other people's drugs just cashed a $700 million check for one it invented itself.
That's not a typo.
That's Glenmark Pharmaceuticals.
And its chairman just said something that should make every generics-first company in India sit up.
"Over the next 10 years, we will be innovation led."
For decades, the Indian pharma playbook was simple: reverse-engineer, manufacture cheap, sell in bulk.
Glenmark just ripped that playbook up.
Last year, its US innovation arm licensed a blood cancer drug candidate — ISB 2001 — to AbbVie.
The numbers still don't feel real:
One deal. Enough to wipe out the company's entire gross debt.
Here's the part nobody talks about.
Before ISB 2001, Glenmark's innovation unit had already burned through 16 other clinical candidates.
Most never made headlines.
"You have to have a solid stomach for failure," said chairman Glenn Saldanha.
From 2000-2004, the company spent more on R&D than it earned in profit.
From 2012-2019, innovation barely paid off at all.
Then one molecule changed the entire trajectory.
Glenmark isn't stopping at one hit.
It's filing for US approval on ISB 2301, a solid-tumour candidate, later this year.
And going forward, it plans one new drug filing every single year.
The playbook: keep India and emerging markets for itself, license the West to giants who can afford billion-dollar trials.
Indian pharma built its global reputation as the world's cheapest pharmacy.
Glenmark is betting that reputation alone won't cut it anymore.
Its stock is already up over 11% in 2026.
If ISB 2001's Phase 1/2 combination trial — kicking off Q3 2026 — delivers, the rest of the oncology pipeline gets a green light too.
A $1.6 billion Indian generics company just proved it can go toe-to-toe with big pharma's own science.
That's not a pivot.
That's a new identity.
That's all for now!
